Clinical trials: Infection Due to Resistant Bacteria
Intracranial Infections
Intraventricular Administration of Intracranial Infections Caused by （Carbapenem-resistant Gram-negative Bacilli）CRGNB
This clinical trial aims to compare two methods of administering polymyxin B for treating severe brain infections caused by carbapenem-resistant Gram-negative bacteria (CRGNB).
- Trial name
- NCT06595979
- Testing
- Polymyxin B
- Where
- 3 sites in China
- Volunteers
- 222 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Bacterial Resistance, Infection Resistant to Multiple Drugs
SATURN 04 Nosocomial Acquisition Study
The study is the WP4 of the EU-funded (7th FW) project SATURN (Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria). A total of 6 surgical and 6 medical wards will participate in the study.
- Conditions
- Bacterial Resistance, Infection Resistant to Multiple Drugs, Staph Aureus Methicillin Resistant Colonization, Infection Due to ESBL Bacteria
- Trial name
- SATURN (NCT01208519)
- Where
- 3 sites in Italy, Romania and 1 more
- Volunteers
- 16,680 people
- Sponsor
- Catholic University of the Sacred Heart
INFECTIONS, Skin and Subcutaneous Tissue Bacterial Infections
Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections
This research will test a new ultra-rapid technology (called ID/AST Accelerate system) that uses a digital microscope to identify bacteria based on their growth patterns.
- Conditions
- INFECTIONS, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
- Trial name
- NCT02796716
- Testing
- Testing on new technology called Accelerate ID/AST system
- Where
- United States
- Volunteers
- 2,102 people
- Sponsor
- Denver Health and Hospital Authority
Infection Due to Resistant Bacteria, Acute Kidney Injury
Colistin Pharmacokinetics in Critically Ill Patients During Extended Dialysis
The emergence of multidrug-resistant bacteria has recently renewed interest in colistin. Data on dosing in critically ill patients undergoing extended dialysis are missing.
- Trial name
- NCT02556190
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Hannover Medical School
Pneumonia, Pneumococcal, Community Acquired Infections
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
- Conditions
- Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
- Trial name
- NCT00035269
- Testing
- Antibiotic
- Where
- 46 sites in United States, Slovakia and 2 more
- Volunteers
- 230 people
- Sponsor
- Pfizer
Bacterial Infections
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
- Trial name
- NCT00035854
- Testing
- Zyvox® / Linezolid
- Where
- 21 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Infection Due to Resistant Bacteria, Pneumonia, Ventilator-Associated
Colistin and Rifampicin for MDR-Acinetobacter
Acinetobacter baumannii causes severe infections (pneumonia, bacteremia, organ space) with high lethality in hospitalised critically ill patients.
- Conditions
- Infection Due to Resistant Bacteria, Pneumonia, Ventilator-Associated, Hospital Acquired Pneumonia, Infection of Bloodstream
- Trial name
- CoRAb (NCT01577862)
- Testing
- Colistin, Rifampicin
- Volunteers
- 210 people
- Sponsor
- University of Campania Luigi Vanvitelli
Bloodstream Infection, Septic Shock
Bloodstream Infection Due to Multidrug-Resistant Organisms - Multicenter Study on Determinants of Clinical Outcomes
Continual surveillance of both community-acquired and nosocomial bloodstream infections for specific target organisms. Analysis of comorbidities, complications, bacterial resistance patterns, bacterial genomics (e. g.
- Trial name
- BLOOMY-COM (NCT03578835)
- Where
- 6 sites in Germany
- Volunteers
- 6,000 people
- Sponsor
- University Hospital Tuebingen
Infection Due to Resistant Organism
Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria
Arbekacin for the use of infection caused by multidrug-resistant organisms
- Trial name
- NCT01659515
- Testing
- Arbekacin Sulfate
- Where
- United States
- Sponsor
- U.S. Army Medical Research and Development Command
Infection, Skin and Subcutaneous Tissue Bacterial Infections
Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections
Military service members and the U.S. veteran population face a growing and serious health threat: widespread antibiotic resistance resulting from resistant bacteria and a dwindling pipe-line of sufficiently potent antibiotics.
- Conditions
- Infection, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
- Trial name
- RAMPED (NCT02060513)
- Where
- 3 sites in United States
- Volunteers
- 2,298 people
- Sponsor
- Connie Price
Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia
A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.
A Phase 3 comparative study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) versus Meropenem (MER) ± Colistin (COL) for the treatment of serious infections due to Gram…
- Conditions
- Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
- Trial name
- REVISIT (NCT03329092)
- Testing
- ATM-AVI, MTZ, MER
- Where
- 157 sites in United States, Argentina and 19 more
- Volunteers
- 422 people
- Sponsor
- Pfizer
Serious Bacterial Infection
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
Phase 3 study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI)…
- Trial name
- NCT03580044
- Testing
- ATM-AVI, BAT
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 15 people
- Sponsor
- Pfizer
Drug Resistance, Microbial
Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria
Carbapenems are a class of antibiotic agents which kill a broad spectrum of bacteria. Infections due to gram-negative bacteria which have acquired resistance to carbapenems are increasing, especially with Klebsiella pneumoniae…
- Trial name
- NCT01041716
- Testing
- None - Observational study
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Maimonides Medical Center
Oncology [See Also, Affected System], Hematological Disease
Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards
This study aims to evaluate the impact of contact isolation on the rate of hospital-acquired transmissions of ESBL-producing Escherichia coli (ESBL-EC) and the rate of colonization and infection.
- Conditions
- Oncology [See Also, Affected System], Hematological Disease, Infection Due to ESBL Escherichia Coli
- Trial name
- CONTAIN (NCT02456818)
- Volunteers
- 2,264 people
- Sponsor
- University of Cologne
Gram-Positive Bacterial Infections
Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria
The purpose of this study is to provide daptomycin, an antibiotic, to patients who are failing conventional therapy, or who cannot take approved antibiotics for one reason or another.
- Trial name
- NCT00055198
- Testing
- daptomycin
- Volunteers
- 75 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Urinary Tract Infections, Enterobacteriaceae Infections
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
This study evaluates the efficacy in achieving clinical cure in non-bacteremic urinary tract infections (UTI) caused by Escherichia coli or Klebsiella pneumoniae producers of extended-spectrum β-lactamases (ESBL) in adult…
- Conditions
- Urinary Tract Infections, Enterobacteriaceae Infections, Infection Due to ESBL Bacteria, Carbapenem
- Trial name
- CAPITIS (NCT03891433)
- Testing
- Meropenem, Ertapenem 1000 MG, Piperacillin, Tazobactam 4-0.5G Solution for Injection
- Where
- Colombia
- Volunteers
- 198 people
- Sponsor
- Universidad del Norte
Infection Due to Resistant Bacteria, Multi-antibiotic Resistance
Resistant Bacteria in Children in France
This study is observational, multicenter and prospective study for surveillance of the use of new antibiotics in pediatrics for treated pediatrics infections due to multi-resistant bacteria
- Conditions
- Infection Due to Resistant Bacteria, Multi-antibiotic Resistance, Antibiotic Prescription, Risk Factors
- Trial name
- BREF (NCT06036628)
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Association Clinique Thérapeutique Infantile du val de Marne
Skin Diseases, Infection
Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects
The main purpose of this study is to compare the safety and efficacy of tigecycline versus clindamycin (including subjects treated with vancomycin) in pediatric subjects (aged 8 to 17 years) with complicated skin and skin…
- Trial name
- NCT00911573
- Testing
- Tigecycline, Clindamycin (or Vancomycin if needed)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Gram-positive Bacterial Infections, Staphylococcal Infections
Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
The main purpose of this study is to find out whether changing the hospital policy to allow switch from glycopeptide antibiotics (given by intravenous drip), to an equally effective oral antibiotic (linezolid) will enable…
- Trial name
- NCT00501150
- Testing
- linezolid
- Where
- United Kingdom
- Volunteers
- 211 people
- Sponsor
- Imperial College London
Infection Due to Resistant Bacteria
International Travel and the Spread of Extended-spectrum Beta-lactamase-producing Escherichia Coli
It is not clear why multi-resistant E. coli (also known as ESBL-producing) have recently became such important causes of infections in patients living and residing in the community.
- Trial name
- NCT01296165
- Testing
- Analysing the behaviours of travellers while visiting India
- Where
- Canada
- Volunteers
- 173 people
- Sponsor
- Johann DD Pitout